These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
177 related articles for article (PubMed ID: 37269300)
21. Sotatercept as a next-generation therapy for pulmonary arterial hypertension: insights from the STELLAR trial. Kopeć G Cardiovasc Res; 2023 Dec; 119(16):e155-e157. PubMed ID: 37584249 [No Abstract] [Full Text] [Related]
22. Novel Mechanisms Targeted by Drug Trials in Pulmonary Arterial Hypertension. Condon DF; Agarwal S; Chakraborty A; Auer N; Vazquez R; Patel H; Zamanian RT; de Jesus Perez VA Chest; 2022 Apr; 161(4):1060-1072. PubMed ID: 34655569 [TBL] [Abstract][Full Text] [Related]
23. Safety and efficacy of RT234 vardenafil inhalation powder on exercise parameters in pulmonary arterial hypertension: phase II, dose-escalation study design. Benza RL; Franco V; Aras MA; Spikes L; Grinnan D; Satler C Respir Res; 2022 Dec; 23(1):355. PubMed ID: 36527025 [TBL] [Abstract][Full Text] [Related]
24. Sotatercept with long-term extension for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes: a phase 2, dose-ranging trial. Komrokji R; Garcia-Manero G; Ades L; Prebet T; Steensma DP; Jurcic JG; Sekeres MA; Berdeja J; Savona MR; Beyne-Rauzy O; Stamatoullas A; DeZern AE; Delaunay J; Borthakur G; Rifkin R; Boyd TE; Laadem A; Vo B; Zhang J; Puccio-Pick M; Attie KM; Fenaux P; List AF Lancet Haematol; 2018 Feb; 5(2):e63-e72. PubMed ID: 29331635 [TBL] [Abstract][Full Text] [Related]
25. A Systematic Review of Novel Therapies of Pulmonary Arterial Hypertension. Nabeh OA; Saud AI; Amin B; Khedr AS; Amr A; Faoosa AM; Esmat E; Mahmoud YM; Hatem A; Mohamed M; Osama A; Soliman YMA; Elkorashy RI; Elmorsy SA Am J Cardiovasc Drugs; 2024 Jan; 24(1):39-54. PubMed ID: 37945977 [TBL] [Abstract][Full Text] [Related]
26. In symptomatic PAH, adding sotatercept to stable background therapy improved 6-min walk distance at 24 wk. Estrada RA Ann Intern Med; 2023 Jun; 176(6):JC69. PubMed ID: 37276594 [TBL] [Abstract][Full Text] [Related]
27. Activin receptor antagonists for cancer-related anemia and bone disease. Fields SZ; Parshad S; Anne M; Raftopoulos H; Alexander MJ; Sherman ML; Laadem A; Sung V; Terpos E Expert Opin Investig Drugs; 2013 Jan; 22(1):87-101. PubMed ID: 23127248 [TBL] [Abstract][Full Text] [Related]
28. Population pharmacokinetic modeling of sotatercept in healthy participants and patients with pulmonary arterial hypertension. Ait-Oudhia S; Jaworowicz D; Hu Z; Bihorel S; Hu S; Balasubrahmanyam B; Mistry B; de Oliveira Pena J; Wenning L; Gheyas F CPT Pharmacometrics Syst Pharmacol; 2024 May; ():. PubMed ID: 38812074 [TBL] [Abstract][Full Text] [Related]
29. Sotatercept Safety and Effects on Hemoglobin, Bone, and Vascular Calcification. Coyne DW; Singh HN; Smith WT; Giuseppi AC; Connarn JN; Sherman ML; Dellanna F; Malluche HH; Hruska KA Kidney Int Rep; 2019 Nov; 4(11):1585-1597. PubMed ID: 31891000 [TBL] [Abstract][Full Text] [Related]
31. Inhibitory Antibodies against Activin A and TGF-β Reduce Self-Supported, but Not Soluble Factors-Induced Growth of Human Pulmonary Arterial Vascular Smooth Muscle Cells in Pulmonary Arterial Hypertension. Kudryashova TV; Shen Y; Pena A; Cronin E; Okorie E; Goncharov DA; Goncharova EA Int J Mol Sci; 2018 Sep; 19(10):. PubMed ID: 30274147 [TBL] [Abstract][Full Text] [Related]
32. Sotatercept, a soluble activin receptor type 2A IgG-Fc fusion protein for the treatment of anemia and bone loss. Raje N; Vallet S Curr Opin Mol Ther; 2010 Oct; 12(5):586-97. PubMed ID: 20886391 [TBL] [Abstract][Full Text] [Related]
33. Luspatercept for the treatment of anemia in myelodysplastic syndromes and primary myelofibrosis. Fenaux P; Kiladjian JJ; Platzbecker U Blood; 2019 Feb; 133(8):790-794. PubMed ID: 30602619 [TBL] [Abstract][Full Text] [Related]
34. Sotatercept (ACE-011) for the treatment of chemotherapy-induced anemia in patients with metastatic breast cancer or advanced or metastatic solid tumors treated with platinum-based chemotherapeutic regimens: results from two phase 2 studies. Raftopoulos H; Laadem A; Hesketh PJ; Goldschmidt J; Gabrail N; Osborne C; Ali M; Sherman ML; Wang D; Glaspy JA; Puccio-Pick M; Zou J; Crawford J Support Care Cancer; 2016 Apr; 24(4):1517-25. PubMed ID: 26370220 [TBL] [Abstract][Full Text] [Related]
35. The Role of Bone Morphogenetic Protein Receptor Type 2 ( Devendran A; Kar S; Bailey R; Trivieri MG Cells; 2022 Nov; 11(23):. PubMed ID: 36497082 [TBL] [Abstract][Full Text] [Related]